Renal transplantation is associated with reduction in the risk for myocardial infarction (MI) in patients with chronic kidney disease requiring long-term dialysis (stage 5D CKD). Whether outcomes of MI differ among renal transplant recipients vs patients with stage 5D CKD or those without CKD has not been well examined.
C ardiovascular disease (CVD) is the leading cause of death in patients with stage 5 chronic kidney disease requiring long-term dialysis (stage 5D CKD). 1 Approximately 45%
of deaths in patients with stage 5D CKD have cardiac causes, with approximately 15% of these deaths attributable to acute myocardial infarction (AMI). 2 Although renal transplantation has been shown to be associated with a reduced risk for CVD in patients with stage 5D CKD, 3, 4 CVD is still a major cause of morbidity and the leading cause of death in renal transplant recipients. 5, 6 Previous studies 7 have shown that compared with the general population, patients with stage 5D CKD are less likely to receive reperfusion therapy for AMI and have more than a 2-fold higher in-hospital mortality rate. Renal transplant recipients have an all-cause mortality benefit compared with patients with stage 5D CKD 8 ; whether this benefit extends to mortality after AMI has not been well examined. In this study, we compare the use of reperfusion (thrombolysis, percutaneous coronary intervention [PCI] , and coronary artery bypass grafting [CABG] ) and in-hospital outcomes of ST-segment elevation myocardial infarction (STEMI) in renal transplant recipients (renal transplant group) vs patients without CKD (non-CKD group) and patients with stage 5D CKD (stage 5D CKD group). We also describe the temporal trends in rates of in-hospital reperfusion and outcomes of STEMI in the renal transplant group.
Methods

Data Source
Data were obtained from the National Inpatient Sample (NIS) data files from January 1, 2003, to December 31, 2013. The design of the NIS has been described previously 9 (eMethods in the Supplement). Briefly, the NIS is the largest publicly available all-payer inpatient health care database in the United States and provides national estimates of hospital stays. The NIS approximates a 20% stratified sample of all discharges from US community hospitals and is drawn from all states participating in the Healthcare Cost and Utilization Project, representing more than 95% of the US population. 9 Patient-and hospitallevel weights were provided to obtain national estimates. 10 This study was deemed exempt from institutional review board approval and the need for informed consent by the institutional review board of New York Medical College because the Healthcare Cost and Utilization Project NIS is a publicly available database containing deidentified patient information.
Study Population
From 2003 to 2013, a total of 86 305 292 discharge records were included in the NIS, corresponding to a national estimate of 424 020 120 hospitalizations in the United States. We used codes 410.01, 410.11 to 410.61, 410.81, and 410.91 from the International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) to identify all patients 18 years or older hospitalized with the principal diagnosis of STEMI (n = 2 912 897). Patients in the stage 5D CKD group (n = 30 072) were identified using the ICD-9-CM diagnosis code for CKD requiring long-term dialysis (585.6) or the ICD-9-CM procedure code for hemodialysis (39.95) or peritoneal dialysis (54.98), except when dialysis was performed for acute kidney injury (584.5-584.9). Patients in the renal transplant group (n = 2980) were identified using the ICD-9-CM diagnosis code V42.0; those who had developed graft failure requiring dialysis were excluded from this group. Of the remaining 2 879 845 patients with STEMI, those in the non-CKD group (n = 2 319 002) were identified as those without documented ICD-9-CM diagnosis codes for CKD (585.1-585.5 and 585.9) (eFigure in the Supplement). This approach has been used by previous studies with the NIS database to identify patients with no CKD, stage 5D CKD, and a functional renal transplant. 1, [11] [12] [13] Also, because the V42.0 diagnosis code has not been extensively validated in the past, we compared the number of overall hospitalizations for AMI in patients with renal transplants captured in the NIS 2013 data vs the US Renal Data System annual data report and found them to be similar. 2 Patients with STEMI who underwent thrombolysis (ICD-9-CM codes 99.10 and V45.88), coronary angiography (ICD-9-CM codes 88.55, 88.56, 37.22, and 37.23), PCI (ICD-9-CM codes 00.66, 36.01, 36.02, 36.05, 36.06, 36.07, and 17.55), and CABG (ICD-9-CM code 36.1x) were identified using the respective ICD-9-CM codes.
Outcomes Measured
Our primary outcome of interest was all-cause, in-hospital mortality, defined by the variable "died" in the NIS database. The mean length of stay (LOS) (in patients surviving to hospital discharge) was used as a secondary outcome.
Patient and Hospital Characteristics
We defined the following baseline patient characteristics: demographics, primary expected payer, weekday vs weekend admission, median household income for the patient's zip code, all Elixhauser comorbidities (except chronic renal failure), 14,15 and other clinically relevant comorbidities (smoking, dyslipidemia, known coronary artery disease [CAD] , family history of CAD, atrial fibrillation, prior MI, prior PCI, prior CABG, and carotid artery disease). A list of ICD-9-CM and Clinical Classification Software codes used to identify comorbidities is given in the eTable 1 in the Supplement. Hospital-level variables included the census region, bed size, location, and teaching status.
1-way analysis of variance for continuous variables. In addition, we used absolute standardized differences (ASD), calculated as the difference in means or proportions divided by a pooled estimate of the SD, to compare baseline characteristics among the 3 groups. Compared with traditional significance testing, ASD is not as sensitive to sample size and is useful in identifying clinically meaningful differences. 16, 17 An ASD of greater than 10% is conventionally considered meaningful. We used multivariable logistic or linear regression models to compare treatment strategy (thrombolysis, coronary angiography, PCI, and CABG), in-hospital mortality, and LOS between the renal transplant group and the non-CKD group or the stage 5D CKD group. All regression models were constructed using generalized estimating equations with exchangeable working correlation matrix to account for clustering of outcomes within hospitals. Variables included in the regression models were age, sex, primary expected payer, weekday vs weekend admission, median household income for the patient's zip code, all Elixhauser and other clinically relevant comorbidities, and hospital characteristics. These variables were selected a priori because they are known to influence STEMI outcomes and in-hospital mortality in administrative databases in general.
14,18,19 Because LOS had a positively skewed distribution, log-transformed LOS was used as the dependent variable in the regression models. For inhospital outcomes, after adjusting for all these variables, we performed additional adjustment for the use of thrombolysis, PCI, and CABG to determine whether differences in treatment could explain outcome differences between the study groups.
To study temporal trends in reperfusion and outcomes of STEMI among renal transplant recipients, we divided the study period into the following intervals: 2003-2004, 2005-2006, 2007-2008, 2009-2010, and 2011-2013 . For trend analyses, Cochrane-Armitage test was used for categorical variables and linear regression for continuous variables. Multivariable logistic or linear regression models adjusting for all the previously mentioned variables were used to assess whether the use of thrombolysis, coronary angiography, PCI, or CABG, inhospital mortality, or LOS in renal transplant recipients with STEMI has changed over time.
Statistical analysis was performed using SPSS Statistics software (version 21.0; IBM Corp). All P values were 2 sided with a significance threshold of less than 0.05. Categorical variables are expressed as percentage and continuous variables as mean (SD). Odds ratios (OR) and 95% CIs are used to report the results of logistic regression. Compared with the non-CKD group, patients in the renal transplant group were more likely to be younger, less likely to be women, less likely to be white, and more likely to be African American or Hispanic. Patients in the renal transplant group had a higher prevalence of prior CABG, uncomplicated or complicated diabetes, hypertension, and deficiency anemia but were less likely to be smokers or to have chronic pulmonary disease. Compared with the stage 5D CKD group, the patients in the renal transplant group were younger, less likely to be women or African American, and more likely to be white. Patients in the renal transplant group had a lower prevalence of most comorbid conditions, including prior MI, prior PCI, prior CABG, atrial fibrillation, heart failure, diabetes with chronic complications, hypertension, peripheral vascular disease, deficiency anemia, chronic pulmonary disease, fluid and electrolyte disorders, and coagulopathy. Dyslipidemia and known CAD were conditions more prevalent in the renal transplant group compared with the stage 5D CKD group (ASD>10% for all comparisons) ( Table 1 and eTable 2 in the Supplement).
Results
Baseline Characteristics
In-Hospital Reperfusion
The renal transplant group with STEMI had lower overall reperfusion rates compared with the non-CKD group (65.2% vs 68.9%; unadjusted OR, 0.85; 95% CI, 0.79-0.91; adjusted OR [AOR], 0.75; 95% CI, 0.68-0.83; P < .001). We found no difference in rates of thrombolysis between the renal transplant and non-CKD groups (3.5% vs 4.0%; AOR, 1.01; 95% CI, 0.84-1.23; P = .89). However, the renal transplant group was less likely to receive coronary angiography (71.8% vs 72.6%; AOR, 0.87; 95% CI, 0.84-1.23; P = .007), PCI (56.2% vs 58.5%; AOR, 0.89; 95% CI, 0.82-0.97; P = .01), or CABG (5.5% vs 6.3%; AOR, 0.72; 95% CI, 0.61-0.85; P < .001) ( Table 2) .
On the contrary, compared with the stage 5D CKD group, the renal transplant group was much more likely to receive reperfusion therapy for STEMI (65.2% vs 39.5%; unadjusted OR, 2.87; 95% CI, 2.65-3.10; AOR, 1.83; 95% CI, 1.67-2.01; P < .001). Thrombolysis was performed in 3.5% of the renal transplant group vs 2.1% of the stage 5D CKD group (AOR, 1.49; 95% CI, 1.17-1.90; P = .001). Coronary angiography was performed in 71.8% of the renal transplant group vs 50.5% of the stage 5D CKD group (AOR, 1.64; 95% CI, 1.49-1.80; P < .001) and PCI in 56.2% of the renal transplant group vs 32.2% of the stage 5D CKD group (AOR, 1.65; 95% CI, 1.51-1.80; P < .001). Rates of CABG use were similar in the renal transplant and stage 5D CKD groups (5.5% vs 6.3%; AOR, 0.96; 95% CI, 0.79-1.16; P = .66) ( Table 2 ).
In-Hospital Outcomes
The renal transplant group with STEMI had similar riskadjusted in-hospital mortality compared with the non-CKD group (8.5% vs 8.4%; AOR, 1.14; 95% CI, 0.99-1.31; P =.08). Even after additional adjustment for differences in the use of thrombolysis, PCI, and CABG, we found no difference in inhospital mortality between the renal transplant and non-CKD groups (AOR, 1.12; 95% CI, 0.97-1.30; P = .12). Likewise, the mean LOS was rather similar between the renal transplant and non-CKD groups (4.8 vs 4.6 days; adjusted parameter estimate, 0.98; 95% CI, 0.97-0.99; P < .001) ( Table 2 ).
In contrast, the renal transplant group had significantly lower risk-adjusted in-hospital mortality compared with the stage 5D CKD group (8.5% vs 23.5%; AOR, 0.37; 95% CI, 0.33- Copyright 2017 American Medical Association. All rights reserved.
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0.43; P < .001), which was not explained by differences in rates of reperfusion between the 2 groups (AOR, 0.40; 95% CI, 0.35-0.46; P < .001). Mean LOS was also shorter in the renal transplant group (4.8 days vs 7.2 days; adjusted parameter estimate: 0.93; 95% CI, 0.92-0.94; P < .001) ( Table 2) . Age-and sex-stratified analysis for in-hospital mortality showed largely similar results ( Table 3) . (Table 4) .
STEMI Trends in Renal Transplant Recipients With STEMI
Discussion
This large, multicenter, nationwide, observational cohort study of patients with STEMI in the United States has several important findings. First, the renal transplant group had modestly lower in-hospital reperfusion rates for STEMI compared with patients without CKD but had similar riskadjusted in-hospital mortality and mean LOS. Second, compared with the stage 5D CKD group, the renal transplant group was much more likely to receive reperfusion and had markedly lower risk-adjusted in-hospital mortality and shorter mean LOS. 
22,23
Secondary hyperparathyroidism and frequent calcium supplementation in patients undergoing dialysis is associated with increased calcium-phosphate product levels, leading to coronary calcification and more calcified plaques.
11,24,25 Also, dialysis status is associated with a generalized inflammatory state that is associated with endothelial dysfunction and accelerated atherosclerosis, leading to greater extent of CAD. 26 Renal transplantation is associated with at least partial correction of these metabolic abnormalities, potentially contributing to a decreased risk for and better outcomes after AMI.
4
Although renal transplant recipients are at lower risk for CVD than patients with stage 5D CKD, they are more prone to develop CVD compared with the general population. Traditional risk scoring systems such as the Framingham risk score underestimate the risk for CAD in renal transplant recipients.
27
To our knowledge, no published data have assessed the outcomes of AMI in renal transplant recipients compared with patients without CKD. We found that despite lower rates of PCI and CABG compared with the non-CKD group, the renal transplant group had similar risk-adjusted in-hospital mortality and mean LOS after STEMI. However, the US Renal Data System data describe 2-year survival rates after AMI in renal transplant recipients to be approximately 50%, 28 whereas, 2-year survival rates after AMI in the general population are reported to be approximately 75%. 29 These data suggest that despite similar in-hospital mortality rates, as noted in our study, renal transplant recipients still have a greater long-term mortality hazard after AMI compared with patients without CKD. Consistent with changes in the general population with STEMI, 30 we observed a temporal decrease in the use of throm- suggesting that outcomes in these patients have improved over time. The temporal change in in-hospital mortality in renal transplant recipients with STEMI is also in stark contrast to the observed change in patients with stage 5D CKD in whom riskadjusted mortality after STEMI has increased during the past few years. 1 
Limitations
Our study has several limitations that must be acknowledged.
Comparison of renal transplant recipients vs patients with stage 5D CKD is subject to some degree of selection bias that is unlikely to be corrected even after extensive multivariable adjustment. Patients who have undergone renal transplant are likely to have undergone some form of screening for CAD and subsequent revascularization as appropriate during the pretransplant workup, which could partly contribute to better outcomes. A more accurate comparison would be between patients undergoing dialysis who are listed for transplant vs those after transplant, but these data were not available in the NIS database. We could not determine the interval between renal transplant and the STEMI event or whether it influences treatment choice or outcomes. Comorbidities were extracted using ICD-9-CM codes, and no adjustment could be made for severity of comorbid conditions. Given the lack of direct access to laboratory data, we could not estimate glomerular filtration rates and relied on ICD-9-CM coding for documentation of CKD. The ICD-9-CM diagnosis of CKD, although highly specific, has a modest sensitivity of approximately 80%
32
; therefore, some patients with milder stages of CKD may have been classified as not having the disease. No data were available on the use of guidelinerecommended adjunctive medical therapies for STEMI. Last, given the observational design of our study, residual measured or unmeasured confounding could have accounted at least partly for our findings.
Conclusions
Compared with patients with stage 5D CKD, renal transplant recipients with STEMI were more likely to undergo reperfusion and had lower risk-adjusted in-hospital mortality. Of note, despite lower reperfusion rates, risk-adjusted in-hospital mortality in renal transplant recipients with STEMI was similar to that in patients without CKD. Among renal transplant recipients with STEMI, we observed a temporal increase in rates of coronary angiography and PCI; however, risk-adjusted in-hospital mortality remained unchanged during the study period. Future investigations are needed to confirm our findings and explore the mechanisms that contribute to improved STEMI outcomes in renal transplant recipients vs those remaining on dialysis. In patients with end-stage renal failure, dialysis (although lifesaving) carries personal and medical burdens unlike any other chronic medical condition. 1 In this population, cardiovascular disease accounts for substantive morbidity and nearly half of their mortality. 2 The gracious gift of a kidney donation from either a living or deceased donor changes every aspect of the recipient's life including reducing their overall mortality.
Both those with chronic kidney disease (CKD) on dialysis and renal transplant recipients are typically excluded from clinical trials of cardiovascular secondary prevention. Furthermore, when conducted, clinical trials in dialysis patients with CKD do not consistently demonstrate the anticipated benefit of secondary prevention therapies (ie, cholesterol reduction with statins) effective in those without CKD. 3 Therefore, little is known about evidence-based therapies in these patients and there is a paucity of knowledge regarding clinicians' patterns of practice even in the setting of common medical conditions such as acute coronary syndromes.
In the current issue of JAMA Cardiology, Gupta and colleagues 4 used the National Inpatient Sample (NIS) database over a decade (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) to address the in-hospital outcomes of ST-segment elevation myocardial infarction (STEMI) patients with CKD on dialysis and renal transplant recipients compared with those without CKD. This database has striking power owing to the sheer magnitude of patients (86 million in 10 years). Analysis of big data repositories, such as the NIS, are required to assess infrequent or rare clinical scenarios, especially when they are highly resource dependent (CKD with dialysis) and/or linked to cherished resources (organ donations). In perspective, STEMI, a reasonably common condition, only represented 3.4% of hospitalizations in the NIS. Further, patients with CKD receiving dialysis represented only 1.0% and prior renal transplantation only 0.1% of the entire STEMI cohort. This elucidates the challenges of systematically studying these clinical conditions through randomized trials or even dedicated multicenter registries. Acknowledging its strengths, the NIS database also has limitations related to "granularity" regarding patient treatment. This includes the lack of temporal characteristics during the index hospitalization such as time from symptom onset to reperfusion and timing of procedures conducted. Indeed, specific to the current analysis, it is unclear whether most patients receiving revascularization did so in the setting of acute reperfusion (ie, primary percutaneous coronary intervention [PCI]) or whether a semiurgent or elective cardiac catheterization led to percutaneous revascularization or coronary artery bypass grafting beyond the time where reperfusion improves outcomes of patients with STEMI. Of patients undergoing cardiac catheterization, only 78% and 80% received PCI for prior renal transplantation and those without CKD, respectively. These rates are lower and arguably somewhat inconsistent with STEMI clinical trials and registries of primary PCI, where greater than 90% typically receive acute reperfusion with primary PCI. Would dedicated efforts to improve timely reperfusion for STEMI in CKD dialysis and renal transplant recipients improve their outcomes? A previous analysis from the same registry demonstrated similar benefits of revascularization in STEMI for CKD dialysis and renal transplant recipients compared with patients without CKD, providing supportive evidence for this hypothesis.
5
While acknowledging the strengths and limitations of the current analysis, what are the key messages? First, patients with CKD on dialysis infrequently receive cardiac catheterization or revascularization/reperfusion in the setting of STEMI. Second, patients with prior renal transplantation have similar rates of cardiac catheterization but lower rates of PCI and coronary artery bypass graft surgery compared with patients with STEMI and without CKD. Finally, after adjusting for age, sex, hospital characteristics, and all comorbidities, prior renal transplant patients have similar in-hospital mortality to patients without CKD and significantly better than their counterparts with CKD on dialysis. The NIS is the largest publicly available all-payer inpatient healthcare database in the U.S. and provides national estimates of hospital inpatient stays. Unweighted, NIS includes data from more than 7 million hospitalizations each year, corresponding to more than 35 million weighted hospitalizations annually. The database contains de-identified clinical and resource-use information included in a typical discharge abstract, including primary and secondary discharge diagnoses and procedures, patient demographics, hospital characteristics, expected payment source, total charges, discharge status, length of stay (LOS), and comorbidity measures. The NIS approximates a 20% stratified sample of all discharges from U.S. community hospitals (defined as "all non-federal, short-term, general, and other specialty hospitals, excluding hospital units of institutions") and is drawn from all states participating in the HCUP, representing more than 95% of the U.S. population. 1 Prior to 2011, NIS comprised of data from all inpatient discharges from a 20% sample of reporting hospitals, stratified by hospital ownership, teaching status, location, bed size, and geographic region. However, in 2012, the database was redesigned to include data from a 20% sample of discharges from all participating hospitals. The self-weighting design of the new NIS reduces the margin of error and delivers more stable and precise estimates compared with the previous versions. 2 For multi-year trend analyses including data from the previous and current designs of the NIS, a new set of discharge trend weights are provided. Cells with absolute values of <11 are labeled as "<0.4%" as the HCUP data use agreement prohibits reporting of fewer than 11 observations to maintain patient confidentiality.
